N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats

Brain Research

Volumn 859, Issue 2, 2000, Pages 286-292

  Guan, Jian ^a   Krishnamurthi, Rita ^a   Waldvogel, Henry J ^b   Faull, Richard L M ^b   Clark, Ross ^a   Gluckman, Peter ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

GPE; Neuroprotection; Parkinson's disease; Rat; Tyrosine hydroxylase

Indexed keywords

GLYCYLPROLYLGLUTAMIC ACID; NEUROPROTECTIVE AGENT; OXIDOPAMINE; SOMATOMEDIN C DERIVATIVE; TRIPEPTIDE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; CELL COUNT; DENERVATION; DOPAMINE; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; MALE; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

EID: 0034708539     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)01988-0     Document Type: Article

References (25)

1. T. Alexi, F. Hefti, Neurotrophin-4/5 selectively protects nigral calbindin-containing neurons in rats with medial forebrain bundle transections, Neuroscience 72 (1996) 911-921.
2. R. Andrew, D.O. Watson, S.A. Best, H. Midgey, The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls, Neurochem. Res. 18 (1993) 1175-1177.
3. J.P. Bourguignon, M.L. Alvarez Gonzalez, A. Gerard, P. Franchimont, Gonadotropin releasing hormone inhibitory autofeedback by subproducts antagonist at N-methyl-D-aspartate receptors: a model of autocrine regulation of peptide secretion, Endocrinology 134 (1994) 1589-1592.
4. L.S. Carman, F.H. Gage, C.W. Shults, Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior, Brain Res. 553 (1991) 275-283.
5. J.H. Fallon, C. Annis, D. Twardzik, L. Gentry, Localization of cells containing transforming growth factor alpha precursor immunoreactivity in the basal ganglia of the adult rat brain, Growth Factors 2 (1990) 241-250.
6. J.H. Fallon, J. Di Salvo, S.E. Loughlin, G. Gimenez-Gallego, Localization of acidic fibroblast growth factor within mouse brain using biochemical and immunocytochemical techniques, Growth Factors 6 (1992) 139-157.
7. J.H. Fallen, S.E. Loughlin, Substantia nigra, in: G. Paxinos (Ed.), The Rat Nervous System. Academic Press, New York, 1994, pp. 215-237.
8. C. Galli, O. Meucci, A. Scorziello, T.M. Werge, Apoptosis in cerebellar granule cells is blocked by high KC1, forskolin, and IGF-1 through distinct mechanisms of action: The involvement of intracellular calcium and RNA synthesis, J. Neurosci. 15 (1995) 1172-1179.
9. Y. Glinka, M. Gassen, M. Youdim, Mechanism of 6-hydroxydopamine neurotoxicity, J. Neural. Transm.: Gen. Sect. Suppl. 50 (1997) 55-60.
10. J. Guan, Insulin-like growth factor-1 after hypoxic-ischemic brain injury: effects and modes of action on neuronal rescue, PhD thesis, 1996, Auckland University, Auckland, New Zealand.
11. J. Guan, H.J. Waldvogel, R.L.M. Faull, P.D. Gluckman, The effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in different regions following hypoxicischemic brain injury in adult rats, Neuroscience 89 (1999) 649-659.
12. J. Guan, C.E. Williams, M. Gunning, E.G. Mallard, The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats, J. Cereb. Blood Flow Metab. 13 (1993) 609-616.
13. J. Guan, C.E. Williams, S.J.M. Skinner, E.G. Mallard, The effects of insulin-like growth factor (IGF)-l, IGF-2, and Des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats -evidence for a role for IGF binding proteins, Endocrinology 137 (1996) 893-898.
14. T. Ikeda, R.J. Waldbillig, D.O. Puro, Truncation of IGF-I yields two mitogens for retinal Muller glial cells, Brain Res. 686 (1995) 87-92.
15. B.S. Jeon, V. Jackson-lewis, R.E. Burke, Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death, Neurodegeneration 4 (2) (1995) 131-137.
16. B.M. Johnston, E.C. Mallard, C.E. Williams, P.D. Gluckman, Insulin-like growth factor-1 is a potent neuronal rescue agent follow-ing hypoxic-ischemic injury in fetal lambs, J. Clin. Invest. 97 (1996) 300-308.
17. P.L. Lapchak, D.M. Gash, F. Collins, D. Hilt, Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): Preclinical development and application to the treatment of Parkinson's disease, Exp. Neurol. 145 (1997) 309-321.
18. 3H]glutamate binding sites in rat brain as determined by quantitative autoradiography, J. Neurosci. (1985) 2909-2919.
19. L. Nilsson-Håkansson, I. Civalero, X. Zhang, C. Carlsson-Skwirut, Effects of IGF-1, truncated IGF-1 and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain, NeuroReport 4 (1993) 1111-1114.
20. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, 1982.
21. V.R. Sara, C. Carlsson-Sdwirut, T. Bergman, H. Jornvall, Indentification of Gly-Pre-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroaction peptide, Biochem. Biophys. Res. Commun. 165 (1989) 766-771.
22. J. Saura, S. Gatti, L. Curatolo, C. Peeters, Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1 in the hippocampus in vitro, NeuroReport 10 (1999) 161-164.
23. H. Yamamoto, L.J. Murphy, Generation of des-(1-3) insulin-like growth factor-I in serum by an acid protease, Endocrinology 135 (1994) 2432-2439.
24. H. Yamamoto, L.J. Murphy, Enzymatic conversion of IGF-I to des(l-3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I action, J. Endocrinol. 146 (1995) 141-148.
25. W.M. Zawada, D.L. Kirschman, J.J. Cohen, K.A. Heidenreich, Growth factors rescue embryonic dopamine neurons from programmed cell death, Exp. Neurol. 140 (1996) 60-67.